The "2019 Annual Summit of China Chemical Pharmaceutical Industry" jointly organized and recommended by China Chemical Pharmaceutical Industry Association, China Pharmaceutical Business Association, China Non-Prescription Drug Association, China Pharmaceutical Enterprise Development Promotion Association and Reed Sinopharm Exhibitions was successfully held in Nanchang, Jiangxi on October 10^th, 2019. During the summit, the list of “Top Ten Chinese Pharmaceutical Industry Enterprise Groups” was released. China Grand Enterprises once again entered the top 10 of the list, which was also its fifth consecutive year in the list.

In addition, Grand Pharmaceutical (China) Co., Ltd., a subsidiary of China Grand Enterprises won the following awards:

• The award of “Top 100 Chemical Pharmaceutical Enterprises in Comprehensive Strength in China in 2019”, ranked 28^th .

• The award of “Excellent Formulation Enterprise Brand in Chemical Pharmaceutical Industry in China in 2019”, ranked 12^th .

• The award of “Raw Material Drug Export-Oriented Outstanding Enterprise Brand in Chemical Pharmaceutical Industry in China in 2019”, ranked 9^th .

• The award of “Outstanding Corporate Brands in Deep Integration and Promotion of Information and Industrialization in Chemical Pharmaceutical Industry in China in 2019” .

• The product “An Ning Pai Enteric Soft Capsule (trade name: Qie Nuo)” was awarded the title of “Excellent Product Brand of Medicines for Other departments of China’s Chemical Pharmaceutical Industry  in 2019”.

Penglai Nuokang Pharmaceutical Co., Ltd., a subsidiary of China Grand Enterprises was awarded:

• The award of “Top 100 Chemical Pharmaceutical Enterprises in Comprehensive Strength in China in 2019”, ranked 85^th .

• The product “Spearhead Viper Hemoglobin for Injection (trade name: Baquting)” won the title of “Excellent Product Brand for Blood and Hematopoietic System in Chemical Pharmaceutical Industry in China in 2019”.

In recent years, China Grand Enterprises Pharmaceutical Health Business (referred to as Grand Health), as an important business area of China Grand Enterprises, adheres to the business principle of being research-oriented, customer-focused and market-driven, and has always taken innovation as its strategic focus. Through the construction of independent research and development platform, industry-university-research collaborative innovation and international cooperation, it has continuously put new products into market, providing guarantee for the high-speed sustainable development of the enterprise.

In the future, Grand Health will continue to adhere to the principle of “quality first, innovation and development”, regards “serving the society” as its highest mission as always, and carry out future business to constantly contribute to the society with innovative cooperation.